New Triple-Threat attack on aggressive lung cancer
NCT ID NCT04728230
Summary
This study is testing a new combination of treatments for people with extensive-stage small cell lung cancer who haven't had treatment yet. It combines a targeted drug (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy, and radiation. The goal is to see if this multi-pronged approach is safe and can better control the cancer's growth and spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.